CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine

Abstract

We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25^pos myeloid blasts in baseline bone marrow. CD25^pos patients had an increased odds of resistance compared to CD25^neg patients (p = .015). In univariate analysis, we found CD25^pos patients had inferior survival compared to CD25^neg (p = .002). In patients with intermediate risk cytogenetics, CD25^pos status stratified patients associating with inferior survival (p = .002). In multivariable analysis, CD25 and TP53 mutations trended towards predicting remission to therapy but were not predictive of survival. Only remission status, ASXL1 and TET2 mutations were found to independently predict overall survival (OS). We conclude CD25 expression identifies patients at risk for resistance to hypomethylating chemotherapy but does not independently predict OS in an older AML population treated with decitabine and plerixafor.

Keywords:

• CD25
• AML
• decitabine
• prognostication
• drug resistance

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1352089.

Additional information

Funding

PC and GA were supported by the following grant: Clinical and Translational Science Center (UL1-TR000457-06). DCH is supported by the Leukemia and Lymphoma Society (LLS 6453-13). MLG and GJR are supported by the following grants (LLS 6453-12, LLS 6427-13; R01 CA102031), MLG is also supported by funds from the Irma T Hirschl Trust. There are no other relevant disclosures to declare by any of the authors.